Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer
Veru Inc. (VERU)
Last veru inc. earnings: 2/12 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
verupharma.com/investors
Company Research
Source: GlobeNewswire
-- Submits Investigational New Drug Application to FDA -- -- Open Label Phase 1b/2 Clinical Trial Expected to Begin before end of 2018 -- MIAMI, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for VERU-111 (bisindole), a first-in-class, next generation, proprietary, oral tubulin inhibitor for the treatment of refractory metastatic prostate cancer. The Company plans to conduct an open label Phase 1b/2 clinical trial in men with metastatic castration resistant prostate cancer that have also become resistant to, or who have failed to respond to, abiraterone or enzalutamide. “Submission of this IND is an important milestone in advancing into humans VERU-111 -- a first-in-class, next generation, proprietary, oral tubulin inhibitor. VERU-111 is being developed for men who have metastatic cast
Show less
Read more
Impact Snapshot
Event Time:
VERU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERU alerts
High impacting Veru Inc. news events
Weekly update
A roundup of the hottest topics
VERU
News
- What Makes Veru (VERU) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock, down previously from $7.00.MarketBeat
- Veru Announces Date of 2024 Annual Meeting of Shareholders [Yahoo! Finance]Yahoo! Finance
- Veru Announces Date of 2024 Annual Meeting of ShareholdersGlobeNewswire
- Veru Inc. (NASDAQ: VERU) is now covered by analysts at Raymond James. They set an "outperform" rating and a $3.00 price target on the stock.MarketBeat
VERU
Earnings
- 8/10/23 - Beat
VERU
Sec Filings
- 4/1/24 - Form DEFA14A
- 4/1/24 - Form 10-Q
- 4/1/24 - Form 10-K/A
- VERU's page on the SEC website